Novo Nordisk Prices Once-Weekly Awiqli Insulin for Indian Market

The Danish pharmaceutical giant is set to roll out its innovative weekly insulin treatment in India next week with a tiered pricing strategy.

MUMBAI — Novo Nordisk India announced today that its highly anticipated once-weekly insulin, Awiqli (insulin icodec), will be commercially available in the Indian market starting next week. The company has finalized the pricing structure for the product, aiming to provide a flexible cost model for patients requiring this long-acting basal insulin treatment.

This launch represents a significant shift in diabetes management, as Awiqli requires only one injection per week, a departure from the traditional once-daily insulin regimens currently standard in the region. The pricing announcement follows the regulatory approvals necessary for the drug’s distribution within the country.

Strategic Pricing and Product Rollout

According to executives at Novo Nordisk India, the pricing for Awiqli has been segmented based on unit dosage requirements to accommodate different patient needs. The company has set the price at ₹2,611 for a single pack containing 700 units. For patients requiring a dosage of 70 units per week, the treatment cost is structured at ₹261 per week. Additionally, a larger pack containing 2,100 units is priced at ₹7,883.

The rollout scheduled for next week is expected to begin through major pharmacy chains and institutional suppliers. Novo Nordisk aims to address the needs of Type 2 diabetes patients who may benefit from the convenience and clinical outcomes associated with a once-weekly injection cycle.

Advancing Diabetes Management

The introduction of Awiqli into the Indian market is part of Novo Nordisk's global effort to reduce the "injection burden" faced by millions of people living with diabetes. By streamlining the frequency of insulin administration, the company intends to improve adherence rates among patients who might otherwise struggle with the complexity of daily regimens.

Clinical data submitted during the regulatory review process highlighted Awiqli’s ability to maintain glucose control over a seven-day period. Medical professionals in India have been closely monitoring the drug's progress, as managing blood sugar levels effectively remains a critical public health challenge in the country.

Official Sources

Statements regarding the product’s launch schedule and pricing tiers were confirmed by Novo Nordisk India leadership. The company emphasized that the distribution strategy is designed to ensure consistent availability across major metropolitan centers as the product hits the market next week.

"According to officials," the pricing tiers were established to ensure that patients have various options based on their prescribed weekly dosage, providing a clear cost framework for healthcare providers and users.

Why It Matters

For patients in India, the primary benefit of Awiqli is the reduced frequency of injections, which can lead to improved quality of life and better long-term glycemic control. For the healthcare system, the shift toward weekly insulin could potentially reduce the management complexity associated with diabetes. Investors and market analysts are observing the launch to see if the pricing strategy succeeds in gaining broad acceptance in a price-sensitive market like India.

Key Facts at a Glance

• Product: Awiqli (insulin icodec), a once-weekly basal insulin.

• Launch Date: Next week.

• Pricing Tiers:

  • ₹261 for 70 units/week.

  • ₹2,611 for a 700-unit pack.

  • ₹7,833 for a 2,100-unit pack.

• Company: Novo Nordisk India.

FAQ

What is Awiqli? Awiqli is a once-weekly basal insulin designed to manage blood glucose levels in patients with Type 2 diabetes, requiring only one injection per week.

When will the drug be available in pharmacies? Novo Nordisk India executives confirmed that the rollout will commence next week across the country.

Why is this insulin different from others? Traditional basal insulin typically requires daily injections; Awiqli is engineered to be effective for a full seven-day cycle, aiming to improve patient compliance.

Are the prices set for all quantities? Yes, the company has released a tiered pricing structure based on unit counts, ranging from ₹261 per week to ₹7,883 for a 2,100-unit pack.

Source: Novo Nordisk India